Pradaxa® (dabigatran) is a prescription blood-thinning medication that has been approved by the Food and Drug Administration (FDA) to reduce the risk of stroke in people with non-valvular atrial fibrillation (AFib).
Pradaxa is in a class of anticoagulant drugs called direct thrombin inhibitors, which attach to clotting agents in the blood and reduce its ability to clot.
Unlike other blood thinners, Pradaxa doesn’t require monthly blood tests and has no known counteracting drug. This can make it more difficult to stop bleeding in patients who are taking Pradaxa. Between October 2010 and August 2011, approximately 1.1 million Pradaxa prescriptions were dispensed from U.S. pharmacies.